[red-beard]

Originally Posted by Geneman

Chloroquine is a bum fock simple drug..... it works by simply slightly changing the pH ( acidity). of small vesicles inside the cell. these are the macro-pinocytic vesicles that bud off the membrane and carry virus ( or the malarial parasite) inside the cell.... when the pH is changed, the vesicle cannot unload its contents into the cell for infection to occur. so eventuially, the contents of the vesicle are degrade, or just routed back outside the cell.

So Cq does not kill the virus, and in fact does not limit binding to the cell or internalization of the virus. It simply inhibits delivery of the virus to the cytoplasm. its is not therapeutic at all, just preventative

problem is that, for it to be effective, you must maintain a reasonably constant level of cq in the bloodstream, meaning constant , consistent dosing.

BTW. it was developed from quinine pills during ww2. also, you can got a reasonable dose of quinine by drinking gin!

It was developed in 1934. Gin was used in India by the British to make daily doses of quinine more palatable. Gin is flavored with Juniper berries.

Tonic Water is limited to around 100 mg/l, which is not enough for protection.

The action you describe does not match the mice studies I posted, which show release of Zinc and inhibiting of replication.

The recent "micro"-trials carried out by the French show both prophylactic and therapeutic properties.

https://www.ncbi.nlm.nih.gov/pubmed/32147496

https://www.sciencedirect.com/science/article/pii/S0166354220301145?via%3Dihub

Recently, Wang and colleagues (Wang et al., 2020) evaluated in vitro five FDA-approved drugs and two broad spectrum antivirals against a clinical isolate of SARS-CoV-2. One of their conclusions was that "chloroquine (is) highly effective in the control of 2019-nCoV infection in vitro" and that its "safety track record suggests that it should be assessed in human patients suffering from the novel coronavirus disease". At least 16 different trials for SARS-CoV-2 already registered in the Chinese Clinical Trial Registry (ChiCTR2000029939, ChiCTR2000029935, ChiCTR2000029899, ChiCTR2000029898, ChiCTR2000029868, ChiCTR2000029837, ChiCTR2000029826, ChiCTR2000029803, ChiCTR2000029762, ChiCTR2000029761, ChiCTR2000029760, ChiCTR2000029741, ChiCTR2000029740, ChiCTR2000029609, ChiCTR2000029559, ChiCTR2000029542) propose to use chloroquine or hydroxychloroquine in the treatment of COVID-19 ("Chinese Clinical Trial Register" (ChiCTR)). In a recent publication (Gao et al., 2020), Gao and colleagues indicate that, "according to the news briefing", "results from more than 100 patients have demonstrated that chloroquine phosphate is superior to the control treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus negative conversion, and shortening the disease course".